Benzinga  Nov 6  Comment 
In a report published Thursday, Credit Suisse analyst Jason Kantor reiterated a Neutral rating and $8.00 price target on Ariad Pharmaceuticals (NASDAQ: ARIA). In the report, Credit Suisse noted, “Iclusig sales increased modestly in the US and...
newratings.com  Oct 27  Comment 
WASHINGTON (dpa-AFX) - Shares of Ariad Pharmaceuticals Inc. (ARIA) have gained more than 60 percent in the last one year, and it looks like the company is slowly getting back in the game. Here's the story of the fall and recovery...
Forbes  Oct 27  Comment 
Investors considering a purchase of ARIAD Pharmaceuticals, Inc. (NASD: ARIA) shares, but cautious about paying the going market price of $5.63/share, might benefit from considering selling puts among the alternative strategies at their disposal....
StreetInsider.com  Oct 24  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ARIAD+Pharma+%28ARIA%29+Updates+on+Final+Recommendation+by+CHMP+for+Iclusig/9939042.html for the full story.
StreetInsider.com  Oct 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/UPDATE%3A+EMA+Panel+Says+Not+Enough+Evidence+for+Lower+Dosing+of+ARIAD+Pharma%27s+%28ARIA%29+Iclusig/9902006.html for the full story.
FierceBiotech  Oct 7  Comment 
Bellicum Pharmaceuticals has switched up its deal with Ariad Pharmaceuticals, agreeing to hand over $50 million for a no-strings-attached license to some cell-signaling technology.
GenEng News  Oct 6  Comment 
Ariad Pharmaceuticals is restructuring a license agreement made with Bellicum Pharmaceuticals for Ariad's cell-signaling technology. Per the revised deal, Bellicum is giving Ariad $50 million in three installments—$15 million upon signing of the...
SeekingAlpha  Oct 5  Comment 
By Mark Romero: What Has Changed Since The Beginning of the Year & Why Has This Stock Become Painful for Investors? Earlier in the year I wrote an article 'Why Now Is The Time To Buy Ariad Pharmaceuticals' and highlighted the potential of...
StreetInsider.com  Oct 2  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ARIAD+Pharma+%28ARIA%29+Reports+AP26113+Receives+FDA+Breakthrough+Therapy+Designation/9879212.html for the full story.


Ariad Pharmaceuticals develops products that use intracellular-signal-transduction pathways to treat disease. It is developing pharmaceuticals that may treat conditions such as anemia, growth-hormone deficiency, cancer, diabetes, asthma, arthritis, and osteoporosis. All of the company's products are in the research or clinical-testing stages. Ariad has not entered any partnerships for the distribution of their product candidates, preferring to have sole control of their development.



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki